Back to Agenda
Part 3 – Developing the Safety Results Section and Guidelines Concerning the Review Process
Session Chair(s)
Diptee A. Gajjar, PhD
Intercontinental Regulatory Strategy Lead
Bristol-Myers Squibb Company, United States
- Safety results
- Adverse events
- Clinical laboratory test findings
- Other safety variables
- Discussion, conclusions, and synopsis
- Review process
Have an account?